Short Interest in IN8bio, Inc. (NASDAQ:INAB) Decreases By 40.8%

IN8bio, Inc. (NASDAQ:INAB) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 20,789 shares, a decline of 40.8% from the June 30th total of 35,117 shares. Based on an average trading volume of 53,283 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.00.

IN8bio Price Performance

IN8bio stock traded up $0.01 during trading hours on Thursday, hitting $1.08. The company had a trading volume of 82,625 shares, compared to its average volume of 65,754. The firm has a 50-day moving average of $1.44 and a 200 day moving average of $1.64. The firm has a market cap of $10.64 million, a PE ratio of -0.41 and a beta of 0.22. IN8bio has a one year low of $0.96 and a one year high of $2.73.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.33. As a group, research analysts expect that IN8bio will post -1.53 earnings per share for the current year.

Institutional Trading of IN8bio

Several institutional investors have recently added to or reduced their stakes in the company. HRT Financial LP acquired a new position in IN8bio in the 4th quarter valued at $34,000. Captrust Financial Advisors bought a new stake in shares of IN8bio in the fourth quarter valued at about $43,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of IN8bio in the fourth quarter valued at about $56,000. Citadel Advisors LLC acquired a new position in shares of IN8bio in the third quarter valued at about $54,000. Finally, Two Sigma Investments LP bought a new position in IN8bio during the third quarter worth about $107,000. 92.05% of the stock is currently owned by institutional investors.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.